Vestar Inc. has received Swedish approval to marketAmBisome, its liposomal form of amphotericin B, as a treatmentfor severe fungal infections, the company announcedWednesday.
The cost of the San Dimas, Calif., company's drug will bereimbursed by the Swedish national health care system at$230 per vial. The price was set as part of the regulatoryapproval process in Sweden, company spokeswoman, MarciaKean told BioWorld.
AmBisome is now approved for sale in 16 European countries,with either full marketing approval or on a compassionate,named-patient basis.
The stock (NASDAQ:VSTR) closed down 25 cents at $22.75.
(c) 1997 American Health Consultants. All rights reserved.